Kalypsys is a pathway-based drug discovery/screening company.
History:
Spun out from the Novartis Genome Research Foundation. They were acquired (or at least the "Kalypsys Systems business unit") by Wako Pure Chemicals in 2010. It is unclear if other parts of the company still remain.
